drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Allogeneic chimeric antigen receptor–engineered natural killer cell therapy (0.5–3×10^9 cells) designed to recognize a disease-relevant antigen and kill antigen-expressing cells; evaluated after lymphodepleting conditioning to enhance engraftment/expansion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor Therapy
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic natural killer cells engineered with a chimeric antigen receptor that binds a disease-relevant antigen and induces killing of antigen-expressing cells via NK effector mechanisms (e.g., perforin/granzyme) triggered by CAR signaling; administered after lymphodepletion to enhance engraftment and expansion.
drug_name
F01 (CAR-NK cells)
nct_id_drug_ref
NCT06468683